StockNews.com Lowers Immunic (NASDAQ:IMUX) to Sell

StockNews.com downgraded shares of Immunic (NASDAQ:IMUX - Free Report) from a hold rating to a sell rating in a report published on Saturday.

Separately, Brookline Capital Management reiterated a buy rating and issued a $10.00 target price on shares of Immunic in a research note on Friday, April 5th.

Immunic Stock Down 3.2 %

IMUX traded down $0.04 during trading on Friday, reaching $1.22. The company had a trading volume of 237,436 shares, compared to its average volume of 262,155. The stock has a market cap of $109.90 million, a P/E ratio of -0.58 and a beta of 2.07. The business has a 50 day simple moving average of $1.33 and a 200-day simple moving average of $1.26. Immunic has a 52 week low of $0.95 and a 52 week high of $3.11.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.03. As a group, equities research analysts expect that Immunic will post -0.99 EPS for the current fiscal year.

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently bought and sold shares of IMUX. Summit Trail Advisors LLC purchased a new position in shares of Immunic during the first quarter valued at $25,000. Sweet Financial Partners LLC purchased a new position in shares of Immunic during the fourth quarter valued at $45,000. Innovis Asset Management LLC increased its stake in shares of Immunic by 46.3% during the third quarter. Innovis Asset Management LLC now owns 272,457 shares of the company's stock valued at $401,000 after buying an additional 86,217 shares during the period. Sierra Summit Advisors LLC purchased a new position in shares of Immunic during the fourth quarter valued at $487,000. Finally, Acadian Asset Management LLC increased its stake in shares of Immunic by 26.8% during the third quarter. Acadian Asset Management LLC now owns 757,250 shares of the company's stock valued at $1,111,000 after buying an additional 159,973 shares during the period. Hedge funds and other institutional investors own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.